Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

A vast majority of drugs that are tested in animals fail to pass human clinical trials, resulting in delayed development and high costs. VeriSIM’s BIOiSIM platform, driven by artificial intelligence (AI) and machine learning (ML), de-risks R&D decisions by providing meaningful insights much earlier in the drug development process with unprecedented accuracy and scalability. This first-in-class solution significantly improves R&D productivity, one of the biggest pain points for pharmaceutical and biotech companies.

Recommended AI News: ADP Advances the Benefit Experience for Large and Medium-sized Businesses with API Integrations

PREDICTIONS-SERIES-2022

Related Posts
1 of 23,219

Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “VeriSIM aligns with Colorcon Ventures’ strategic focus on improving efficiencies in the drug development process. We believe VeriSIM can lower overall pharmaceutical development cost and accelerate time to market.”

Jo Varshney, VeriSIM’s Founder and CEO, said, “We are pleased to have Colorcon join us as a strategic investor. Access to Colorcon’s global R&D relationships and expertise should prove helpful as we scale VeriSIM in the years ahead.”

Colorcon Ventures joins a prominent list of investors who also participated in VeriSIM’s recently announced Series A, including Morpheus Ventures, Debiopharm Innovation Fund, OCA Ventures, Intel Capital, Serra Ventures and Susa Ventures.

Recommended AI News: Numonix Expands Compliance and Business Features for Its IXCloud Compliance Recording Service for Microsoft Teams

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.